NASDAQ · EPRX
Eupraxia Pharmaceuticals Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for EPRX: Nov 3, 2026
Eupraxia Pharmaceuticals Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.26. The reported EPS for the same quarter last year was $-0.19.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.26 | $-0.22 | $-0.32 | 6 |
| Dec 2026 | $-0.28 | $-0.23 | $-0.36 | 6 |
| Mar 2027 | $-0.24 | $-0.21 | $-0.29 | 3 |
| Jun 2027 | $-0.25 | $-0.19 | $-0.32 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Sep 2, 11:20 PM EDT6 Biotech Stocks To Watch Ahead Of Key Catalysts: RenovoRx, Eupraxia, Connect Bio, Kardigan & More(RTTNews) – Today, we bring you a list of six stocks to watch in the coming days and months. Each company has potentially market-moving catalysts on the horizon, ranging from clinical data readouts and investor conference presentations to key FDA decisions. These binary events ca
- Zacks · Aug 10, 9:55 AM EDTWall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- RTTNews · Jul 14, 2:03 AM EDTEupraxia Pharmaceuticals Appoints New Technical Operations Heads; Co-Founder Malone Steps Down(RTTNews) – Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company, announced several leadership changes within the company to support its upcoming planned phase of clinical and commercial growth.
- Fintel · May 21, 8:02 PM EDTStifel Initiates Coverage of Eupraxia Pharmaceuticals (EPRX) with Buy RecommendationFintel reports that on May 21, 2026, Stifel initiated coverage of Eupraxia Pharmaceuticals (NasdaqCM:EPRX) with a Buy recommendation. Analyst Price Forecast Suggests 89.83% Upside
- RTTNews · May 13, 7:24 AM EDTEupraxia Records $12 Mln Loss In Q1; Advances EP-104GI For Treatment Of EoE(RTTNews) – Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company, on Tuesday released its first quarter financial results.
- RTTNews · May 6, 10:36 AM EDTEupraxia Releases EoEHSS Sub Score Data From Phase 1b/2a Trial For EP-104GI In Treating EoE(RTTNews) – Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company, on Wednesday announced the first release of sub-score data from the eosinophilic esophagitis histologic scoring system (EoEHSS) used in the Phase 1b/2a part of the RESOLVE trial evaluating E
- RTTNews · Apr 21, 7:58 AM EDTEupraxia Reports Positive 36-Week Data For EP-104GI In RESOLVE Trial In Eosinophilic Esophagitis(RTTNews) – Eupraxia Pharmaceuticals Inc. (EPRX) on Tuesday reported positive 36-week data from the highest dose cohort in its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis.
- Zacks · Apr 2, 6:03 AM EDTNew Strong Sell Stocks for April 2ndACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.
- Fintel · Mar 23, 8:04 PM EDTWilliam Blair Initiates Coverage of Eupraxia Pharmaceuticals (EPRX) with Outperform RecommendationFintel reports that on March 23, 2026, William Blair initiated coverage of Eupraxia Pharmaceuticals (NasdaqCM:EPRX) with a Outperform recommendation. Analyst Price Forecast Suggests 47.48% Upside
- RTTNews · Feb 19, 8:19 AM ESTEupraxia Pharma Prices $55 Mln Offering Of Shares And Warrants; Stock Down(RTTNews) – Eupraxia Pharmaceuticals Inc. (EPRX) , a clinical-stage biotechnology company, announced the pricing of the public offering of 6.43 million shares at a price of $7 per share and pre-funded warrants to purchase up to 1.43 million shares at a price of US$6.9999. The gro
- RTTNews · Feb 19, 5:30 AM ESTEupraxia Prices $55 Mln Offering To Advance Diffusphere Pipeline(RTTNews) – Eupraxia Pharmaceuticals Inc. (EPRX) announced it has priced a US$55 million public offering of common shares and pre-funded warrants. The financing is expected to close on or about February 20, 2026, subject to customary conditions.
- Fintel · Jan 14, 9:12 AM ESTEupraxia Pharmaceuticals (EPRX) Price Target Increased by 21.61% to 10.82The average one-year price target for Eupraxia Pharmaceuticals (NasdaqCM:EPRX) has been revised to $10.82 / share. This is an increase of 21.61% from the prior estimate of $8.90 dated December 20, 2025. The price target is an average of many targets provided b
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Eupraxia Pharmaceuticals Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.